X4 Pharmaceuticals
XFOR
53 hedge funds and large institutions have $67.4M invested in X4 Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 5 closing their positions.
119% more capital inflows, than outflows
Capital inflows: $2.93M | Capital outflows: $1.34M
69% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 13
1.08% more ownership
Funds ownership: 63.24% → 64.32% (+1.1%)
0% more funds holding
Funds holding: 53 → 53 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$681K |
| 2 |
Ikarian Capital
Dallas,
Texas
|
+$666K |
| 3 |
BlackRock
New York
|
+$310K |
| 4 |
JP Morgan Chase
New York
|
+$200K |
| 5 |
Minot Wealth Management
Westwood,
Massachusetts
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$508K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$151K |
| 3 |
RA Capital Management
Boston,
Massachusetts
|
-$148K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$132K |
| 5 |
State Street
Boston,
Massachusetts
|
-$86.2K |
XFOR Hedge Fund Activity: Q4 2020 in Review
53 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2020, worth a combined $67.4M — down 2.7% from $69.3M a quarter earlier.
Fund positioning in XFOR was balanced in Q4 2020: 5 funds opened new positions, 5 closed out, 22 added to existing stakes and 13 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $681K. The largest seller was Opaleye Management, exiting entirely with an estimated $508K sold.
- 53 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $67.4M of X4 Pharmaceuticals stock for Q4 2020, down 2.7% quarter-over-quarter.
- 5 funds opened new X4 Pharmaceuticals positions in Q4 2020 and 5 closed out, a net change of 0 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2020 was Cormorant Asset Management, an estimated $681K added.
- The largest X4 Pharmaceuticals seller in Q4 2020 was Opaleye Management, an estimated $508K sold.
Based on aggregated 13F filings for Q4 2020.